ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA

BACKGROUND: Recurrent glioblastoma has a poor median overall survival despite multimodal treatment. The use of pembrolizumab, an anti-PD-1 monoclonal antibody, demonstrates promise, including improved overall survival and increased immune response, when used in the neoadjuvant setting. METHODS: We e...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Chow, Frances, Mochizuki, Aaron, Lee, Alexander, Galvez, Mildred, Orpilla, Joey, Everson, Richard, Liau, Linda, Cloughesy, Timothy, Prins, Robert
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Adult Clinical Trials–Immunologic
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847707/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.016
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg